سرطان الغدد الليمفاوية الجريبي المنتكس المقاوم للريتوكسيماب (Rit-R) — ماذا تفعل بعد ذلك

References

• Therapeutic options for people with relapsed disease are more limited for those who are resistant to rituximab (Rit-R), i.e., people who did not respond or who progressed during or within 6 months after treatment with rituximab or a rituximab-containing regimen.
• Offer bendamustine in combination with obinutuzumab, for those people who are rituximab refractory.
• A Phase 3 study has demonstrated evidence for a benefit of obinutuzumab (see section Management of patients with newly diagnosed FL), when combined with bendamustine and followed by obinutuzumab maintenance for 2 years, compared with bendamustine alone.